
SANUWAVE Health, Inc.
80
Recent developments include a credit agreement amendment with a fee payment, quarterly earnings calls providing operational insights, and preliminary revenue reports showing mixed trends.
- SANUWAVE Health, Inc. entered a credit agreement amendment and waiver, agreeing to pay a $5,000 fee in October 2026 [N1].
- The company held its Q2 2026 earnings call and released transcripts and highlights detailing operational performance [N2][N3].
- Preliminary Q2 2026 revenue slipped year over year but exceeded revised guidance [N4].
- Record preliminary revenues were reported for Q4 2025, with $13.3–$13.4 million, marking a 29–30% increase year-over-year [N6].
SANUWAVE Health, Inc. is a healthcare company specializing in medical technologies primarily focused on wound care. The company generates revenue through sales of its medical devices and related products. Recent quarterly financial disclosures show revenues in the range of several million dollars with ongoing net losses. The company maintains liquidity with cash and current assets exceeding current liabilities as of the latest quarter. Operational updates and earnings calls provide transparency into revenue trends and strategic initiatives.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. SANUWAVE Health, Inc. reported $8.579 million in revenue and a net loss of $1.416 million for the quarter ended September 30, 2026, with liquidity ratios indicating a current ratio of 1.18 and cash ratio of 0.4 as of that date [S2]. Recent news and earnings calls provide detailed insights into business operations and financial trends [N1][N2][N3][N4].
The company has demonstrated revenue growth with record quarterly and full-year revenues reported in recent periods. Strategic executive appointments and inclusion in recognized indices support potential for commercial expansion. The company maintains liquidity above current liabilities, supporting operational continuity.
SANUWAVE continues to report net losses and faces risks related to cybersecurity and information technology dependencies. Revenue variability is evident with some quarters showing year-over-year revenue declines. The company’s liquidity ratios, while above 1, indicate moderate cushion against short-term obligations. Credit agreement amendments suggest ongoing financing considerations.
SANUWAVE's moat appears to be based on its specialized medical technology in wound care and its ability to achieve record revenues in recent periods. Inclusion in the Russell 2000 Index and executive hires aimed at commercial growth suggest efforts to strengthen market position. However, the company faces typical healthcare sector risks including regulatory, technological, and competitive challenges.
• Cybersecurity and IT Risks: The company is dependent on information technology systems which face risks including cybersecurity breaches and data leakage [S1][S2].
• Financial Performance Risks: SANUWAVE has reported net losses and revenue variability, which may impact financial stability and operational funding.
• Liquidity and Financing Risks: Current ratio of 1.18 and cash ratio of 0.4 indicate moderate liquidity; recent credit agreement amendments imply ongoing financing management.
Business trends: Revenue growth with record quarterly and full-year revenues alongside some variability; strategic focus on wound care market expansion.
Execution milestones: Recent credit agreement amendment, executive appointments to commercial operations, and multiple earnings calls providing transparency.
Key risks: Cybersecurity and IT system vulnerabilities, ongoing net losses with revenue fluctuations, and moderate liquidity requiring financial management.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- SANUWAVE Health, Inc. operates in the healthcare sector with a focus on wound care and related medical technologies.
- As of the quarter ended September 30, 2026, the company reported revenue of $8.579 million and a net loss of $1.416 million, with basic and diluted EPS of -$0.16 per share, according to its 10-Q filing [S2].
- The company had cash and cash equivalents of approximately $6.569 million and current assets of $19.299 million against current liabilities of $16.394 million, resulting in a current ratio of 1.18 and a cash ratio of 0.4 as of September 30, 2026 [S2].
- SANUWAVE's recent quarterly earnings calls and transcripts provide insights into operational performance and revenue trends, including Q2 2026 earnings call and Q1 2026 earnings call highlights [N2][N3][N7][N8].
- Recent news indicates the company entered a credit agreement amendment and waiver, agreeing to pay a $5,000 fee in October 2026 [N1].
- Preliminary Q2 2026 revenue slipped year over year but topped revised guidance, indicating some variability in revenue performance [N4].
- The company has achieved record quarterly and full-year revenues in prior periods, with Q4 2025 preliminary revenue reported between $13.3 million and $13.4 million, up 29-30% year-over-year [N6].
- SANUWAVE has made executive appointments to drive growth in the wound care market, including appointing Dustin Libby as EVP of Commercial Operations [N5].
- The company is included in the 2025 Russell 2000 Index, indicating recognition within small-cap equities [N5].
- Risk factors disclosed in SEC filings include dependency on information technology systems and cybersecurity risks [S1][S2].
Generated 2026-11-11
- N2
- N3
- N6
- N7
- N8
- S1 | 2026-03-26 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-10-29 | www.nasdaq.com | SANUWAVE Health, Inc. Enters Credit Agreement Amendment and Waiver, Agrees to Pay $5,000 Fee | https://www.nasdaq.com/articles/sanuwave-health-inc-enters-credit-agreement-amendment-and-waiver-agrees-pay-5000-fee
- N2 | 2026-08-13 | www.nasdaq.com | SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/sanuwave-snwv-q2-2026-earnings-call-transcript
- N3 | 2026-08-07 | www.nasdaq.com | Sanuwave Health Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/sanuwave-health-q2-earnings-call-highlights
- N4 | 2026-07-14 | www.nasdaq.com | Sanuwave's Preliminary Q2 Revenue Slips Year Over Year But Tops Revised Guidance; Stock Up | https://www.nasdaq.com/articles/sanuwaves-preliminary-q2-revenue-slips-year-over-year-tops-revised-guidance-stock
- N5 | 2026-07-10 | www.nasdaq.com | Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-vrax-jumps-100-after-fosun-deal-fbrx-soars-vitiligo-data-trax-watch
- N6 | 2026-06-01 | www.nasdaq.com | Sanuwave (SNWV) Q4 2025 Earnings Transcript | https://www.nasdaq.com/articles/sanuwave-snwv-q4-2025-earnings-transcript
- N7 | 2026-05-13 | www.nasdaq.com | Sanuwave (SNWV) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/sanuwave-snwv-q1-2026-earnings-transcript
- N8 | 2026-05-13 | www.nasdaq.com | Sanuwave Health Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/sanuwave-health-q1-earnings-call-highlights
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


